Bristol Myers (BMY) had a terrible year.

Since Jan. 1, BMY plummeted from about $72.50 to $50.10 – where insiders seem to be confident a bottom may be in place. On November 20, for example, director Theodore Samuels paid $423,400 for 8,500 Bristol Myers shares. Then, on November 28, CEO Chris Boerner bought 3,071 shares for about $150,000.

To see a super simple way to predict market direction, click here.

Even better, as investors wait for the BMY stock to recover, they can collect its yield of 4.55%. We expect to see a new dividend announcement from the company this month, as well. Plus, not only is BMY technically oversold, it’s trading at nearly half of growth, with a PEG of 0.59.

With patience, we’d like to see BMY initially refill its bearish gap around $55.


Ian Cooper